Pharmaceutical
Medical
Health

Abbott

$79.96
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$1.13 (1.43%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell Abbott and other stocks, options, ETFs, and crypto commission-free!

About

Abbott Laboratories engages in the discovery, development, manufacture, and sale of a broad and diversified line of health care products. It operates through the following segments: Established Pharmaceutical Products, Nutritional Products, Diagnostic Products, Cardiovascular and Neuromodulation Products, and Other. Read More The Established Pharmaceutical Products segment refers to the international sales of a line of branded generic pharmaceutical products. The Nutritional Products segment caters to the worldwide sales of adult and pediatric nutritional products. The Diagnostic Products segment markets diagnostic systems and tests for blood banks, hospitals, commercial laboratories, and alternate-care testing sites. The Vascular Products segment trades coronary, endovascular, structural heart, vessel closure, and other medical device products. The Other segment comprises of Abbott Medical Optics. The company was founded by Wallace Calvin Abbott in 1888 and is headquartered in Abbott Park, IL.

Employees
103,000
Headquarters
Abbott Park, Illinois
Founded
1888
Market Cap
138.40B
Price-Earnings Ratio
60.14
Dividend Yield
1.60
Average Volume
6.08M
High Today
$80.25
Low Today
$79.02
Open Price
$79.18
Volume
1.88M
52 Week High
$80.25
52 Week Low
$56.81

Collections

Pharmaceutical
Medical
Health
Medical Devices
Healthcare
Manufacturing
Technology
US

News

Yahoo Finance15h

What Makes Abbott (ABT) a New Buy Stock

Abbott (ABT) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. Abbott (ABT) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices. The sole determinant of the Zacks rating is a company's changing earnings picture. The Zac...

148
Yahoo Finance15h

Abbott's (ABT) MitraClip COAPT Trial Shows Favorable Results

Abbott Lifesciences ABT recently announced favorable results from two distinctly-conducted analyses of the two-year long COAPT (Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients with Functional Mitral Regurgitation) clinical trial.

10
Seeking Alpha18h

Abbott's Alinity m CE Mark'd

Abbott (NYSE:ABT) announces that its Alinity m molecular diagnostic system is now CE Mark certified. Initial assays include HIV-1, hepatitis B and C viruses, Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis, Mycoplasma genitalium and high-risk HPV. The product is not approved in the U.S....

38

Earnings

$0.58
$0.66
$0.73
$0.81
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
Actual
Expected Apr 17, Pre-Market
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.